



**Fourth Quarter 2022**  
**Other Financial Disclosures**  
**Table of Contents**

Table 1: Sales by Segment	1
Table 2: Sales by Geographic Area	2
Table 3: Sales of Key Products/Franchises	3 - 8
Table 3a: Supplemental Sales Reconciliation	9
Table 4: Condensed Consolidated Statement of Earnings - QTD	10
Table 5: Condensed Consolidated Statement of Earnings - YTD	11
Table 6: Non-GAAP Adjusted Operational Sales Growth - QTD	12
Table 7: Non-GAAP Adjusted Operational Sales Growth - YTD	13
Table 8: Non-GAAP Adjusted Net Earnings	14
Table 9: Non-GAAP IBT by Segment - QTD	15
Table 10: Non-GAAP IBT by Segment - YTD	16
Table 11: Non-GAAP P&L Reconciliation	17

**Johnson & Johnson and Subsidiaries**
**Supplementary Sales Data**

(Unaudited; Dollars in Millions)

	FOURTH QUARTER				
	2022	2021	Total	Percent Change	
				Operations	Currency
<b>Sales to customers by segment of business</b>					
Consumer Health <sup>(1)</sup>					
U.S.	\$ 1,696	1,529	10.9 %	10.9	-
International	2,071	2,199	(5.8)	3.2	(9.0)
	<b>3,767</b>	<b>3,728</b>	1.0	6.4	(5.4)
Pharmaceutical <sup>(1)</sup>					
U.S.	7,375	7,418	(0.6)	(0.6)	-
International	5,788	6,799	(14.9)	(4.5)	(10.4)
	<b>13,163</b>	<b>14,217</b>	(7.4)	(2.5)	(4.9)
Pharmaceutical excluding COVID-19 Vaccine <sup>(1,3)</sup>					
U.S.	7,375	7,205	2.4	2.4	-
International	5,099	5,394	(5.5)	6.0	(11.5)
	<b>12,474</b>	<b>12,599</b>	(1.0)	3.9	(4.9)
MedTech <sup>(2)</sup>					
U.S.	3,445	3,216	7.1	7.1	-
International	3,331	3,643	(8.6)	2.9	(11.5)
	<b>6,776</b>	<b>6,859</b>	(1.2)	4.9	(6.1)
U.S.	12,516	12,163	2.9	2.9	-
International	11,190	12,641	(11.5)	(1.1)	(10.4)
Worldwide	<b>23,706</b>	<b>24,804</b>	(4.4)	0.9	(5.3)
U.S.	12,516	11,950	4.7	4.7	-
International	10,501	11,236	(6.5)	4.4	(10.9)
Worldwide excluding COVID-19 Vaccine <sup>(3)</sup>	\$ <b>23,017</b>	<b>23,186</b>	(0.7) %	4.6	(5.3)

	TWELVE MONTHS				
	2022	2021	Total	Percent Change	
				Operations	Currency
Consumer Health <sup>(1)</sup>					
U.S.	\$ 6,599	6,516	1.3 %	1.3	-
International	8,354	8,519	(1.9)	5.3	(7.2)
	<b>14,953</b>	<b>15,035</b>	(0.5)	3.6	(4.1)
Pharmaceutical <sup>(1)</sup>					
U.S.	28,604	27,954	2.3	2.3	-
International	23,959	23,726	1.0	11.9	(10.9)
	<b>52,563</b>	<b>51,680</b>	1.7	6.7	(5.0)
Pharmaceutical excluding COVID-19 Vaccine <sup>(1,3)</sup>					
U.S.	28,484	27,320	4.3	4.3	-
International	21,900	21,975	(0.3)	10.3	(10.6)
	<b>50,384</b>	<b>49,295</b>	2.2	6.9	(4.7)
MedTech <sup>(2)</sup>					
U.S.	13,377	12,686	5.4	5.4	-
International	14,050	14,374	(2.3)	6.9	(9.2)
	<b>27,427</b>	<b>27,060</b>	1.4	6.2	(4.8)
U.S.	48,580	47,156	3.0	3.0	-
International	46,363	46,619	(0.6)	9.1	(9.7)
Worldwide	<b>94,943</b>	<b>93,775</b>	1.3	6.1	(4.8)
U.S.	48,460	46,522	4.2	4.2	-
International	44,304	44,868	(1.3)	8.2	(9.5)
Worldwide excluding COVID-19 Vaccine <sup>(3)</sup>	\$ <b>92,764</b>	<b>91,390</b>	1.5 %	6.2	(4.7)

**Note:** Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

<sup>(1)</sup> Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes.

<sup>(2)</sup> Previously referred to as Medical Devices.

<sup>(3)</sup> Refer to supplemental sales reconciliation schedule.

**Johnson & Johnson and Subsidiaries**

**Supplementary Sales Data**

(Unaudited; Dollars in Millions)

	FOURTH QUARTER				
	2022	2021	Total	Percent Change	
				Operations	Currency
<b>Sales to customers by geographic area</b>					
U.S.	\$ 12,516	12,163	2.9 %	2.9	-
Europe	5,816	6,925	(16.0)	(6.3)	(9.7)
Western Hemisphere excluding U.S.	1,545	1,459	5.9	11.8	(5.9)
Asia-Pacific, Africa	3,829	4,257	(10.0)	3.1	(13.1)
International	11,190	12,641	(11.5)	(1.1)	(10.4)
Worldwide	\$ 23,706	24,804	(4.4) %	0.9	(5.3)

	TWELVE MONTHS				
	2022	2021	Total	Percent Change	
				Operations	Currency
	\$ 48,580	47,156	3.0 %	3.0	-
	23,449	23,594	(0.6)	11.0	(11.6)
	6,125	5,750	6.5	10.2	(3.7)
	16,789	17,275	(2.8)	6.2	(9.0)
	46,363	46,619	(0.6)	9.1	(9.7)
	\$ 94,943	93,775	1.3 %	6.1	(4.8)

**Note:** Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FOURTH QUARTER				
	2022	2021	% Change		
			Reported	Operational <sup>(1)</sup>	Currency
<b>CONSUMER HEALTH SEGMENT<sup>(2,3)</sup></b>					
<u>OTC</u>					
US	\$ 754	633	18.9%	18.9%	-
Intl	815	811	0.6%	9.6%	-9.0%
WW	1,569	1,444	8.6%	13.7%	-5.1%
<u>SKIN HEALTH / BEAUTY</u>					
US	573	538	6.5%	6.5%	-
Intl	515	546	-5.6%	4.4%	-10.0%
WW	1,088	1,084	0.4%	5.4%	-5.0%
<u>ORAL CARE</u>					
US	164	159	3.3%	3.3%	-
Intl	207	246	-16.0%	-8.1%	-7.9%
WW	370	405	-8.4%	-3.7%	-4.7%
<u>BABY CARE</u>					
US	93	90	3.4%	3.4%	-
Intl	264	309	-14.6%	-7.4%	-7.2%
WW	356	399	-10.6%	-5.0%	-5.6%
<u>WOMEN'S HEALTH</u>					
US	4	4	15.6%	15.6%	-
Intl	217	230	-5.7%	4.4%	-10.1%
WW	220	233	-5.5%	4.6%	-10.1%
<u>WOUND CARE / OTHER</u>					
US	109	106	3.3%	3.3%	-
Intl	54	57	-7.5%	2.9%	-10.4%
WW	163	164	-0.5%	3.1%	-3.6%
<b>TOTAL CONSUMER HEALTH</b>					
US	1,696	1,529	10.9%	10.9%	-
Intl	2,071	2,199	-5.8%	3.2%	-9.0%
WW	\$ 3,767	3,728	1.0%	6.4%	-5.4%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	TWELVE MONTHS				
	2022	2021	% Change		
			Reported	Operational <sup>(1)</sup>	Currency
<b>CONSUMER HEALTH SEGMENT<sup>(2,3)</sup></b>					
<u>OTC</u>					
US	\$ 2,782	2,594	7.3%	7.3%	-
Intl	3,249	3,034	7.1%	14.5%	-7.4%
WW	6,031	5,627	7.2%	11.2%	-4.0%
<u>SKIN HEALTH / BEAUTY</u>					
US	2,337	2,400	-2.6%	-2.6%	-
Intl	2,015	2,141	-5.9%	2.2%	-8.1%
WW	4,352	4,541	-4.2%	-0.4%	-3.8%
<u>ORAL CARE</u>					
US	635	637	-0.3%	-0.3%	-
Intl	871	1,008	-13.6%	-7.4%	-6.2%
WW	1,505	1,645	-8.5%	-4.7%	-3.8%
<u>BABY CARE</u>					
US	357	378	-5.5%	-5.5%	-
Intl	1,104	1,188	-7.1%	-1.4%	-5.7%
WW	1,461	1,566	-6.7%	-2.4%	-4.3%
<u>WOMEN'S HEALTH</u>					
US	13	13	1.7%	1.7%	-
Intl	891	905	-1.5%	7.1%	-8.6%
WW	904	917	-1.5%	7.0%	-8.5%
<u>WOUND CARE / OTHER</u>					
US	475	495	-4.0%	-4.0%	-
Intl	224	243	-8.0%	-3.4%	-4.6%
WW	700	739	-5.3%	-3.8%	-1.5%
<b>TOTAL CONSUMER HEALTH</b>					
US	6,599	6,516	1.3%	1.3%	-
Intl	8,354	8,519	-1.9%	5.3%	-7.2%
WW	\$ 14,953	15,035	-0.5%	3.6%	-4.1%

See footnotes at end of schedule

PHARMACEUTICAL SEGMENT <sup>(2,3)</sup>	REPORTED SALES vs. PRIOR PERIOD (\$MM)					REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	FOURTH QUARTER					TWELVE MONTHS				
	2022	2021	% Change			2022	2021	% Change		
		Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency	
<b>IMMUNOLOGY</b>										
US	\$ 2,805	2,912	-3.6%	-3.6%	-	\$ 11,036	10,843	1.8%	1.8%	-
Intl	1,312	1,443	-9.1%	2.1%	-11.2%	5,899	5,907	-0.1%	10.3%	-10.4%
WW	4,118	4,355	-5.4%	-1.8%	-3.6%	16,935	16,750	1.1%	4.8%	-3.7%
<b>REMICADE</b>										
US	318	511	-37.7%	-37.7%	-	1,417	2,019	-29.8%	-29.8%	-
US Exports <sup>(4)</sup>	41	39	5.1%	5.1%	-	204	236	-13.6%	-13.6%	-
Intl	116	214	-45.9%	-41.3%	-4.6%	722	935	-22.8%	-18.7%	-4.1%
WW	475	764	-37.8%	-36.5%	-1.3%	2,343	3,190	-26.6%	-25.3%	-1.3%
<b>SIMPONI / SIMPONI ARIA</b>										
US	280	287	-2.2%	-2.2%	-	1,166	1,127	3.5%	3.5%	-
Intl	220	271	-18.6%	-7.4%	-11.2%	1,017	1,148	-11.4%	-1.4%	-10.0%
WW	501	559	-10.2%	-4.7%	-5.5%	2,184	2,276	-4.0%	1.0%	-5.0%
<b>STELARA</b>										
US	1,621	1,542	5.2%	5.2%	-	6,388	5,938	7.6%	7.6%	-
Intl	764	792	-3.5%	8.1%	-11.6%	3,335	3,196	4.4%	15.7%	-11.3%
WW	2,386	2,334	2.3%	6.2%	-3.9%	9,723	9,134	6.5%	10.4%	-3.9%
<b>TREMFYA</b>										
US	541	528	2.5%	2.5%	-	1,844	1,503	22.7%	22.7%	-
Intl	211	165	27.5%	44.5%	-17.0%	824	624	32.0%	47.8%	-15.8%
WW	752	693	8.5%	12.5%	-4.0%	2,668	2,127	25.4%	30.1%	-4.7%
<b>OTHER IMMUNOLOGY</b>										
US	3	6	-53.5%	-53.5%	-	17	21	-18.4%	-18.4%	-
Intl	0	0	*	*	*	0	3	*	*	*
WW	3	6	-53.3%	-53.3%	0.0%	17	24	-28.2%	-28.2%	0.0%
<b>INFECTIOUS DISEASES</b>										
US	414	614	-32.6%	-32.6%	-	1,680	2,249	-25.3%	-25.3%	-
Intl	1,127	1,818	-38.0%	-31.0%	-7.0%	3,769	3,576	5.4%	17.3%	-11.9%
WW	1,540	2,431	-36.6%	-31.4%	-5.2%	5,449	5,825	-6.5%	0.8%	-7.3%
<b>COVID-19 VACCINE</b>										
US	0	213	*	*	-	120	634	-81.1%	-81.1%	-
Intl	689	1,405	-50.9%	-45.0%	-5.9%	2,059	1,751	17.6%	32.1%	-14.5%
WW	689	1,619	-57.4%	-52.2%	-5.2%	2,179	2,385	-8.6%	2.0%	-10.6%
<b>EDURANT / rilpivirine</b>										
US	9	10	1.2%	1.2%	-	36	41	-10.8%	-10.8%	-
Intl	281	220	27.6%	39.2%	-11.6%	972	953	2.0%	12.7%	-10.7%
WW	290	230	26.5%	37.6%	-11.1%	1,008	994	1.5%	11.8%	-10.3%
<b>PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA</b>										
US	398	380	4.7%	4.7%	-	1,494	1,508	-1.0%	-1.0%	-
Intl	95	135	-29.5%	-20.5%	-9.0%	449	575	-21.9%	-13.4%	-8.5%
WW	493	515	-4.3%	-1.9%	-2.4%	1,943	2,083	-6.7%	-4.4%	-2.3%
<b>OTHER INFECTIOUS DISEASES</b>										
US	6	11	-47.1%	-47.1%	-	30	66	-55.5%	-55.5%	-
Intl	61	57	7.3%	18.0%	-10.7%	289	297	-2.6%	3.6%	-6.2%
WW	67	68	-1.6%	7.4%	-9.0%	318	363	-12.3%	-7.2%	-5.1%

	REPORTED SALES vs. PRIOR PERIOD (\$MM)					REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	FOURTH QUARTER					TWELVE MONTHS				
	2022	2021	% Change			2022	2021	% Change		
		Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency	
<b>NEUROSCIENCE</b>										
US	912	899	1.4%	1.4%	-	3,570	3,347	6.7%	6.7%	-
Intl	825	890	-7.2%	3.3%	-10.5%	3,323	3,641	-8.7%	0.4%	-9.1%
WW	1,737	1,789	-2.8%	2.4%	-5.2%	6,893	6,988	-1.4%	3.4%	-4.8%
<u>CONCERTA / Methylophenidate</u>										
US	37	55	-34.3%	-34.3%	-	151	172	-12.5%	-12.5%	-
Intl	131	123	6.5%	20.3%	-13.8%	493	495	-0.4%	9.9%	-10.3%
WW	168	178	-6.2%	3.4%	-9.6%	644	667	-3.5%	4.1%	-7.6%
<u>INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</u>										
US	678	668	1.8%	1.8%	-	2,714	2,550	6.5%	6.5%	-
Intl	329	361	-8.8%	2.7%	-11.5%	1,426	1,472	-3.1%	7.8%	-10.9%
WW	1,008	1,029	-2.0%	2.1%	-4.1%	4,140	4,022	3.0%	6.9%	-3.9%
<u>RISPERDAL CONSTA</u>										
US	62	77	-19.4%	-19.4%	-	257	287	-10.4%	-10.4%	-
Intl	50	63	-21.5%	-9.7%	-11.8%	228	305	-25.3%	-15.5%	-9.8%
WW	112	140	-20.4%	-15.0%	-5.4%	485	592	-18.1%	-13.0%	-5.1%
<u>OTHER NEUROSCIENCE</u>										
US	134	99	35.5%	35.5%	-	447	338	32.4%	32.4%	-
Intl	315	342	-7.7%	0.3%	-8.0%	1,176	1,368	-14.1%	-7.5%	-6.6%
WW	449	441	2.0%	8.2%	-6.2%	1,623	1,706	-4.9%	0.4%	-5.3%
<b>ONCOLOGY</b>										
US	1,857	1,594	16.5%	16.5%	-	6,930	5,958	16.3%	16.3%	-
Intl	2,069	2,184	-5.3%	6.8%	-12.1%	9,052	8,590	5.4%	17.3%	-11.9%
WW	3,927	3,778	3.9%	10.9%	-7.0%	15,983	14,548	9.9%	16.9%	-7.0%
<u>DARZALEX</u>										
US	1,139	867	31.4%	31.4%	-	4,210	3,169	32.8%	32.8%	-
Intl	944	778	21.3%	36.7%	-15.4%	3,767	2,854	32.0%	47.0%	-15.0%
WW	2,083	1,645	26.6%	33.9%	-7.3%	7,977	6,023	32.4%	39.5%	-7.1%
<u>ERLEADA</u>										
US	275	235	17.2%	17.2%	-	968	813	19.2%	19.2%	-
Intl	266	149	78.0%	97.8%	-19.8%	913	478	*	*	*
WW	541	384	40.9%	48.6%	-7.7%	1,881	1,291	45.7%	53.0%	-7.3%
<u>IMBRUVICA</u>										
US	318	436	-27.0%	-27.0%	-	1,390	1,747	-20.4%	-20.4%	-
Intl	547	626	-12.5%	-2.0%	-10.5%	2,394	2,622	-8.7%	1.0%	-9.7%
WW	866	1,062	-18.5%	-12.3%	-6.2%	3,784	4,369	-13.4%	-7.6%	-5.8%
<u>ZYTIGA / abiraterone acetate</u>										
US	20	23	-14.3%	-14.3%	-	74	119	-37.8%	-37.8%	-
Intl	250	525	-52.4%	-44.8%	-7.6%	1,696	2,178	-22.1%	-12.3%	-9.8%
WW	270	548	-50.8%	-43.6%	-7.2%	1,770	2,297	-22.9%	-13.6%	-9.3%
<u>OTHER ONCOLOGY</u>										
US	106	34	*	*	-	289	110	*	*	-
Intl	63	106	-41.1%	-33.1%	-8.0%	283	458	-38.3%	-31.6%	-6.7%
WW	168	140	20.6%	26.7%	-6.1%	571	568	0.6%	6.0%	-5.4%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FOURTH QUARTER					TWELVE MONTHS				
	2022	2021	% Change			2022	2021	% Change		
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency
<b><u>PULMONARY HYPERTENSION</u></b>										
US	610	587	3.9%	3.9%	-	2,346	2,365	-0.8%	-0.8%	-
Intl	261	264	-1.3%	13.5%	-14.8%	1,071	1,085	-1.3%	11.2%	-12.5%
WW	870	851	2.3%	6.9%	-4.6%	3,417	3,450	-1.0%	3.0%	-4.0%
<b><u>OPSUMIT</u></b>										
US	305	286	7.0%	7.0%	-	1,132	1,147	-1.3%	-1.3%	-
Intl	156	162	-3.7%	11.0%	-14.7%	651	672	-3.2%	9.3%	-12.5%
WW	461	448	3.1%	8.4%	-5.3%	1,783	1,819	-2.0%	2.6%	-4.6%
<b><u>UPTRAVI</u></b>										
US	280	264	6.3%	6.3%	-	1,104	1,056	4.5%	4.5%	-
Intl	56	46	20.4%	33.3%	-12.9%	218	181	20.4%	32.4%	-12.0%
WW	336	310	8.4%	10.3%	-1.9%	1,322	1,237	6.9%	8.6%	-1.7%
<b><u>OTHER PULMONARY HYPERTENSION</u></b>										
US	24	38	-35.5%	-35.5%	-	110	163	-32.3%	-32.3%	-
Intl	48	56	-12.2%	4.4%	-16.6%	202	232	-12.8%	0.3%	-13.1%
WW	73	94	-21.7%	-11.8%	-9.9%	313	395	-20.8%	-13.1%	-7.7%
<b><u>CARDIOVASCULAR / METABOLISM / OTHER</u></b>										
US	776	813	-4.4%	-4.4%	-	3,042	3,192	-4.7%	-4.7%	-
Intl	194	200	-3.4%	5.7%	-9.1%	845	927	-8.9%	-1.7%	-7.2%
WW	971	1,013	-4.2%	-2.4%	-1.8%	3,887	4,119	-5.6%	-4.0%	-1.6%
<b><u>XARELTO</u></b>										
US	667	644	3.4%	3.4%	-	2,473	2,438	1.4%	1.4%	-
Intl	-	-	-	-	-	-	-	-	-	-
WW	667	644	3.4%	3.4%	-	2,473	2,438	1.4%	1.4%	-
<b><u>INVOKANA / INVOKAMET</u></b>										
US	29	59	-51.3%	-51.3%	-	193	308	-37.4%	-37.4%	-
Intl	62	60	2.3%	11.2%	-8.9%	255	254	0.1%	7.3%	-7.2%
WW	91	120	-24.1%	-19.6%	-4.5%	448	563	-20.4%	-17.2%	-3.2%
<b><u>OTHER</u></b>										
US	81	110	-25.7%	-25.7%	-	376	446	-15.5%	-15.5%	-
Intl	132	140	-5.9%	3.3%	-9.2%	590	673	-12.3%	-5.1%	-7.2%
WW	213	250	-14.6%	-9.4%	-5.2%	966	1,119	-13.6%	-9.3%	-4.3%
<b><u>TOTAL PHARMACEUTICAL</u></b>										
US	7,375	7,418	-0.6%	-0.6%	-	28,604	27,954	2.3%	2.3%	-
Intl	5,788	6,799	-14.9%	-4.5%	-10.4%	23,959	23,726	1.0%	11.9%	-10.9%
WW	\$ 13,163	\$ 14,217	-7.4%	-2.5%	-4.9%	\$ 52,563	\$ 51,680	1.7%	6.7%	-5.0%

See footnotes at end of schedule

**MEDTECH SEGMENT** <sup>(2,3,5)</sup>

**INTERVENTIONAL SOLUTIONS**

	2022		2021		% Change	
	2022	2021	Reported	Operational <sup>(1)</sup>	Currency	
US	\$ 603	483	24.9%	24.9%	-	
Intl	495	536	-7.6%	6.2%	-13.8%	
WW	1,098	1,019	7.8%	15.1%	-7.3%	

**ORTHOPAEDICS**

	2022		2021		% Change	
	2022	2021	Reported	Operational <sup>(1)</sup>	Currency	
US	1,385	1,305	6.1%	6.1%	-	
Intl	763	851	-10.4%	0.8%	-11.2%	
WW	2,148	2,155	-0.4%	4.0%	-4.4%	

**HIPS**

	2022		2021		% Change	
	2022	2021	Reported	Operational <sup>(1)</sup>	Currency	
US	250	227	9.7%	9.7%	-	
Intl	135	151	-10.4%	0.4%	-10.8%	
WW	385	378	1.7%	6.0%	-4.3%	

**KNEES**

	2022		2021		% Change	
	2022	2021	Reported	Operational <sup>(1)</sup>	Currency	
US	231	208	11.8%	11.8%	-	
Intl	122	135	-9.5%	1.2%	-10.7%	
WW	354	342	3.4%	7.6%	-4.2%	

**TRAUMA**

	2022		2021		% Change	
	2022	2021	Reported	Operational <sup>(1)</sup>	Currency	
US	470	467	0.7%	0.7%	-	
Intl	240	261	-7.9%	3.5%	-11.4%	
WW	710	728	-2.4%	1.7%	-4.1%	

**SPINE, SPORTS & OTHER**

	2022		2021		% Change	
	2022	2021	Reported	Operational <sup>(1)</sup>	Currency	
US	434	403	7.5%	7.5%	-	
Intl	265	304	-12.9%	-1.5%	-11.4%	
WW	699	708	-1.3%	3.6%	-4.9%	

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

**FOURTH QUARTER**

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

**TWELVE MONTHS**



	REPORTED SALES vs. PRIOR PERIOD (\$MM)					REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	FOURTH QUARTER					TWELVE MONTHS				
	2022	2021	Reported	% Change Operational <sup>(1)</sup>	Currency	2022	2021	Reported	% Change Operational <sup>(1)</sup>	Currency
<b>SURGERY</b>										
US	1,000	986	1.5%	1.5%	-	3,897	3,867	0.8%	0.8%	-
Intl	1,383	1,527	-9.4%	1.4%	-10.8%	5,793	5,945	-2.6%	5.7%	-8.3%
WW	<u>2,384</u>	<u>2,513</u>	-5.1%	1.4%	-6.5%	<u>9,690</u>	<u>9,812</u>	-1.2%	3.8%	-5.0%
<b>ADVANCED</b>										
US	456	457	-0.2%	-0.2%	-	1,784	1,761	1.3%	1.3%	-
Intl	653	735	-11.1%	-0.4%	-10.7%	2,785	2,861	-2.6%	5.3%	-7.9%
WW	<u>1,109</u>	<u>1,192</u>	-7.0%	-0.3%	-6.7%	<u>4,569</u>	<u>4,622</u>	-1.1%	3.8%	-4.9%
<b>GENERAL</b>										
US	544	528	3.1%	3.1%	-	2,113	2,105	0.4%	0.4%	-
Intl	731	793	-7.8%	3.0%	-10.8%	3,008	3,085	-2.5%	6.2%	-8.7%
WW	<u>1,275</u>	<u>1,321</u>	-3.5%	3.0%	-6.5%	<u>5,121</u>	<u>5,190</u>	-1.3%	3.8%	-5.1%
<b>VISION</b>										
US	456	443	3.1%	3.1%	-	1,990	1,857	7.2%	7.2%	-
Intl	689	728	-5.4%	5.9%	-11.3%	2,859	2,831	1.0%	11.1%	-10.1%
WW	<u>1,145</u>	<u>1,171</u>	-2.2%	4.8%	-7.0%	<u>4,849</u>	<u>4,688</u>	3.4%	9.5%	-6.1%
<b>CONTACT LENSES / OTHER</b>										
US	343	316	8.6%	8.6%	-	1,522	1,398	8.9%	8.9%	-
Intl	489	518	-5.6%	7.2%	-12.8%	2,022	2,043	-1.0%	10.1%	-11.1%
WW	<u>831</u>	<u>833</u>	-0.2%	7.7%	-7.9%	<u>3,543</u>	<u>3,440</u>	3.0%	9.6%	-6.6%
<b>SURGICAL</b>										
US	113	126	-10.7%	-10.7%	-	468	459	2.0%	2.0%	-
Intl	200	211	-5.0%	2.9%	-7.9%	837	788	6.2%	13.7%	-7.5%
WW	<u>314</u>	<u>338</u>	-7.1%	-2.2%	-4.9%	<u>1,306</u>	<u>1,248</u>	4.6%	9.4%	-4.8%
<b>TOTAL MEDTECH</b>										
US	3,445	3,216	7.1%	7.1%	-	13,377	12,686	5.4%	5.4%	-
Intl	3,331	3,643	-8.6%	2.9%	-11.5%	14,050	14,374	-2.3%	6.9%	-9.2%
WW	<u>\$ 6,776</u>	<u>\$ 6,859</u>	-1.2%	4.9%	-6.1%	<u>\$ 27,427</u>	<u>\$ 27,060</u>	1.4%	6.2%	-4.8%

Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely

\* Percentage greater than 100% or not meaningful

(1) Operational growth excludes the effect of translational currency

(2) Unaudited

(3) Certain prior year amounts have been reclassified to conform to current year product disclosures

(4) Reported as U.S. sales

(5) Previously referred to as Medical Devices

**Supplemental Sales Reconciliation (Unaudited)**

(Dollars in Millions)

	FOURTH QUARTER					TWELVE MONTHS				
	Percent Change					Percent Change				
	2022	2021	Total	Operations	Currency	2022	2021	Total	Operations	Currency
<b>Pharmaceutical</b>										
U.S.	\$ 7,375	7,418	(0.6) %	(0.6)	-	\$ 28,604	27,954	2.3 %	2.3	-
International	5,788	6,799	(14.9)	(4.5)	(10.4)	23,959	23,726	1.0	11.9	(10.9)
Worldwide	13,163	14,217	(7.4)	(2.5)	(4.9)	52,563	51,680	1.7	6.7	(5.0)
COVID-19 Vaccine										
U.S.	0	213	*	*	-	120	634	(81.1)	(81.1)	-
International	689	1,405	(50.9)	(45.0)	(5.9)	2,059	1,751	17.6	32.1	(14.5)
Worldwide	689	1,619	(57.4)	(52.2)	(5.2)	2,179	2,385	(8.6)	2.0	(10.6)
Pharmaceutical excluding COVID-19 Vaccine										
U.S.	7,375	7,205	2.4	2.4	-	28,484	27,320	4.3	4.3	-
International	5,099	5,394	(5.5)	6.0	(11.5)	21,900	21,975	(0.3)	10.3	(10.6)
Worldwide	12,474	12,599	(1.0)	3.9	(4.9)	50,384	49,295	2.2	6.9	(4.7)
<b>Worldwide</b>										
U.S.	12,516	12,163	2.9	2.9	-	48,580	47,156	3.0	3.0	-
International	11,190	12,641	(11.5)	(1.1)	(10.4)	46,363	46,619	(0.6)	9.1	(9.7)
Worldwide	23,706	24,804	(4.4)	0.9	(5.3)	94,943	93,775	1.3	6.1	(4.8)
COVID-19 Vaccine										
U.S.	0	213	*	*	-	120	634	(81.1)	(81.1)	-
International	689	1,405	(50.9)	(45.0)	(5.9)	2,059	1,751	17.6	32.1	(14.5)
Worldwide	689	1,619	(57.4)	(52.2)	(5.2)	2,179	2,385	(8.6)	2.0	(10.6)
Worldwide										
U.S.	12,516	11,950	4.7	4.7	-	48,460	46,522	4.2	4.2	-
International	10,501	11,236	(6.5)	4.4	(10.9)	44,304	44,868	(1.3)	8.2	(9.5)
Worldwide excluding COVID-19 Vaccine	\$ 23,017	23,186	(0.7) %	4.6	(5.3)	\$ 92,764	91,390	1.5 %	6.2	(4.7)

**Note:** Columns and rows within tables may not add due to rounding

\* Percentage greater than 100% or not meaningful

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

	FOURTH QUARTER				
	2022		2021		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$ 23,706	100.0	\$ 24,804	100.0	(4.4)
Cost of products sold	7,765	32.8	7,955	32.1	(2.4)
Gross Profit	15,941	67.2	16,849	67.9	(5.4)
Selling, marketing and administrative expenses	6,512	27.4	7,154	28.9	(9.0)
Research and development expense	3,841	16.2	4,720	19.0	(18.6)
In-process research and development	173	0.7	0	0.0	
Interest (income) expense, net	(77)	(0.3)	47	0.2	
Other (income) expense, net	1,207	5.1	9	0.0	
Restructuring	84	0.4	83	0.3	
Earnings before provision for taxes on income	4,201	17.7	4,836	19.5	(13.1)
Provision for taxes on income	681	2.9	100	0.4	581.0
Net earnings	\$ 3,520	14.8	\$ 4,736	19.1	(25.7)
Net earnings per share (Diluted)	\$ 1.33		\$ 1.77		(24.9)
Average shares outstanding (Diluted)	2,650.1		2,670.2		
Effective tax rate	16.2 %		2.1 %		
<b>Adjusted earnings before provision for taxes and net earnings <sup>(1)</sup></b>					
Earnings before provision for taxes on income	\$ 7,418	31.3	\$ 6,339	25.6	17.0
Net earnings	\$ 6,218	26.2	\$ 5,678	22.9	9.5
Net earnings per share (Diluted)	\$ 2.35		\$ 2.13		10.3
Effective tax rate	16.2 %		10.4 %		

<sup>(1)</sup> See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

	TWELVE MONTHS				
	2022		2021		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$ 94,943	100.0	\$ 93,775	100.0	1.3
Cost of products sold	31,089	32.7	29,855	31.8	4.1
Gross Profit	63,854	67.3	63,920	68.2	(0.1)
Selling, marketing and administrative expenses	24,765	26.1	24,659	26.3	0.4
Research and development expense	14,603	15.4	14,714	15.7	(0.8)
In-process research and development	783	0.8	900	1.0	
Interest (income) expense, net	(214)	(0.2)	130	0.1	
Other (income) expense, net	1,871	2.0	489	0.5	
Restructuring	321	0.3	252	0.3	
Earnings before provision for taxes on income	21,725	22.9	22,776	24.3	(4.6)
Provision for taxes on income	3,784	4.0	1,898	2.0	99.4
Net earnings	\$ 17,941	18.9	\$ 20,878	22.3	(14.1)
Net earnings per share (Diluted)	\$ 6.73		\$ 7.81		(13.8)
Average shares outstanding (Diluted)	2,663.9		2,674.0		
Effective tax rate	17.4 %		8.3 %		
<b>Adjusted earnings before provision for taxes and net earnings <sup>(1)</sup></b>					
Earnings before provision for taxes on income	\$ 31,880	33.6	\$ 30,464	32.5	4.6
Net earnings	\$ 27,038	28.5	\$ 26,195	27.9	3.2
Net earnings per share (Diluted)	\$ 10.15		\$ 9.80		3.6
Effective tax rate	15.2 %		14.0 %		

<sup>(1)</sup> See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries  
Reconciliation of Non-GAAP Financial Measure

Adjusted Operational Sales Growth  
FOURTH QUARTER 2022 ACTUAL vs. 2021 ACTUAL

	Segments			
	Consumer Health	Pharmaceutical	MedTech	Total
<b>WW As Reported</b>	<b>1.0%</b>	<b>(7.4)%</b>	<b>(1.2)%</b>	<b>(4.4)%</b>
U.S.	10.9%	(0.6)%	7.1%	2.9%
International	(5.8)%	(14.9)%	(8.6)%	(11.5)%
<b>WW Currency</b>	<b>(5.4)</b>	<b>(4.9)</b>	<b>(6.1)</b>	<b>(5.3)</b>
U.S.	-	-	-	-
International	(9.0)	(10.4)	(11.5)	(10.4)
<b>WW Operational</b>	<b>6.4%</b>	<b>(2.5)%</b>	<b>4.9%</b>	<b>0.9%</b>
U.S.	10.9%	(0.6)%	7.1%	2.9%
International	3.2%	(4.5)%	2.9%	(1.1)%
<b>Interventional Solutions</b>				
<b>Abiomed</b>			<b>(0.5)</b>	<b>(0.1)</b>
U.S.			(1.0)	(0.3)
International			0.0	0.0
<b>All Other Acquisitions and Divestitures</b>	<b>0.0</b>	<b>0.2</b>	<b>0.0</b>	<b>0.1</b>
U.S.	0.1	0.2	(0.2)	0.1
International	0.0	0.1	0.1	0.1
<b>WW Adjusted Operational</b>	<b>6.4%</b>	<b>(2.3)%</b>	<b>4.4%</b>	<b>0.8%</b>
U.S.	11.0%	(0.4)%	5.9%	2.7%
International	3.2%	(4.4)%	3.0%	(1.0)%

**Note:** Percentages are based on actual, non-rounded figures and may not sum.

Johnson & Johnson and Subsidiaries  
Reconciliation of Non-GAAP Financial Measure

**Adjusted Operational Sales Growth**  
**TWELVE MONTHS 2022 ACTUAL vs. 2021 ACTUAL**

	Segments			
	<u>Consumer Health</u>	<u>Pharmaceutical</u>	<u>MedTech</u>	<u>Total</u>
<b>WW As Reported</b>	<b>(0.5)%</b>	<b>1.7%</b>	<b>1.4%</b>	<b>1.3%</b>
U.S.	1.3%	2.3%	5.4%	3.0%
International	(1.9)%	1.0%	(2.3)%	(0.6)%
<b>WW Currency</b>	<b>(4.1)</b>	<b>(5.0)</b>	<b>(4.8)</b>	<b>(4.8)</b>
U.S.	-	-	-	-
International	(7.2)	(10.9)	(9.2)	(9.7)
<b>WW Operational</b>	<b>3.6%</b>	<b>6.7%</b>	<b>6.2%</b>	<b>6.1%</b>
U.S.	1.3%	2.3%	5.4%	3.0%
International	5.3%	11.9%	6.9%	9.1%
<b>All Other Acquisitions and Divestitures</b>	<b>0.3</b>	<b>0.1</b>	<b>(0.1)</b>	<b>0.1</b>
U.S.	0.2	0.2	(0.4)	0.0
International	0.5	0.1	0.1	0.2
<b>WW Adjusted Operational</b>	<b>3.9%</b>	<b>6.8%</b>	<b>6.1%</b>	<b>6.2%</b>
U.S.	1.5%	2.5%	5.0%	3.0%
International	5.8%	12.0%	7.0%	9.3%

**Note:** Percentages are based on actual, non-rounded figures and may not sum.

**Johnson & Johnson and Subsidiaries**

**Reconciliation of Non-GAAP Financial Measures**

(Dollars in Millions Except Per Share Data)	Fourth Quarter		Twelve Months Ended	
	2022	2021	2022	2021
Net Earnings, after tax- as reported	\$3,520	\$4,736	\$17,941	\$20,878
Pre-tax Adjustments				
Intangible Asset Amortization expense	1,061	1,121	4,305	4,697
Litigation related	262	274	866	2,328
IPR&D	173	-	783	900
Restructuring related	140	140	463	473
Acquisition, integration and divestiture related <sup>1</sup>	196	26	196	(478)
(Gains)/losses on securities	6	(198)	690	(533)
Medical Device Regulation <sup>2</sup>	88	73	296	234
COVID-19 Vaccine related costs <sup>3</sup>	821	-	1,474	-
Consumer Health separation costs	470	67	1,089	67
Other	-	-	(7)	-
Tax Adjustments				
Tax impact on special item adjustments <sup>4</sup>	(507)	(184)	(1,592)	(1,281)
Consumer Health separation tax related costs	35	-	494	-
Tax legislation and other tax related	(47)	(377)	40	(1,090)
Adjusted Net Earnings, after tax	<b>\$6,218</b>	<b>\$5,678</b>	<b>\$27,038</b>	<b>\$26,195</b>
Average shares outstanding (Diluted)	2,650.1	2,670.2	2,663.9	2,674.0
Adjusted net earnings per share (Diluted)	<b>\$2.35</b>	<b>\$2.13</b>	<b>\$10.15</b>	<b>\$9.80</b>
Operational adjusted net earnings per share (Diluted)	<b>\$2.46</b>		<b>\$10.70</b>	

**Notes:**

<sup>1</sup> Acquisition, integration and divestiture related for 2022 primarily includes costs related to the Abiomed acquisition. Acquisition, integration and divestiture related for 2021 primarily includes the gain on the divestiture of two Pharmaceutical brands outside of the U.S.

<sup>2</sup> European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company's previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance which is expected to be completed during 2024.

<sup>3</sup> COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's modification of its COVID-19 vaccine research program and manufacturing capacity to levels that meet all remaining customer contractual requirements.

<sup>4</sup> The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

Johnson & Johnson and Subsidiaries  
Reconciliation of Non-GAAP Financial Measures

Q4 QTD - Income Before Tax by Segment\*  
Dollars in Millions

	Consumer Health <sup>1</sup>		Pharmaceutical <sup>1</sup>		MedTech		Unallocated		Consumer Health Separation Costs		Worldwide Total	
	2022	2021	2022	2021	2022	2021	2022	2021	2022	2021	2022	2021
Reported Income Before Tax by Segment	\$ 651	442	3,308	4,306	865	575	(153)	(420)	(470)	(67)	4,201	4,836
<b>% to Sales</b>	<b>17.3%</b>	<b>11.9%</b>	<b>25.1%</b>	<b>30.3%</b>	<b>12.8%</b>	<b>8.4%</b>	<b>-0.6%</b>	<b>-1.7%</b>	<b>-2.0%</b>	<b>-0.3%</b>	<b>17.7%</b>	<b>19.5%</b>
Intangible asset amortization expense	84	100	717	761	260	260	-	-	-	-	1,061	1,121
In-process research and development	-	-	173	-	-	-	-	-	-	-	173	-
Litigation related	72	122	61	(35)	129	187	-	-	-	-	262	274
Loss/(gain) on securities	-	1	23	(237)	(17)	38	-	-	-	-	6	(198)
Restructuring related	21	28	31	22	88	90	-	-	-	-	140	140
Acquisition, integration and divestiture related	-	-	(104)	5	300	21	-	-	-	-	196	26
Medical Device Regulation	-	-	-	-	88	73	-	-	-	-	88	73
COVID-19 Vaccine related costs	-	-	821	-	-	-	-	-	-	-	821	-
Consumer Health separation costs	-	-	-	-	-	-	-	-	470	67	470	67
Other	-	-	-	-	-	-	-	-	-	-	-	-
Adjusted Income Before Tax by Segment	\$ <u>828</u>	<u>693</u>	<u>5,030</u>	<u>4,822</u>	<u>1,713</u>	<u>1,244</u>	<u>(153)</u>	<u>(420)</u>	<u>-</u>	<u>-</u>	<u>7,418</u>	<u>6,339</u>
<b>% to Sales</b>	<b>22.0%</b>	<b>18.6%</b>	<b>38.2%</b>	<b>33.9%</b>	<b>25.3%</b>	<b>18.1%</b>	<b>-0.6%</b>	<b>-1.7%</b>	<b>0.0%</b>	<b>0.0%</b>	<b>31.3%</b>	<b>25.6%</b>

<sup>1</sup> Prior year income before tax has been reclassified as Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes

\*Estimated as of 1/24/2023



Johnson & Johnson and Subsidiaries  
Reconciliation of Non-GAAP Financial Measures

Q4 YTD - Income Before Tax by Segment\*  
Dollars in Millions

	Consumer Health <sup>1</sup>		Pharmaceutical <sup>1</sup>		MedTech		Unallocated		Consumer Health Separation Costs		Worldwide Total	
	2022	2021	2022	2021	2022	2021	2022	2021	2022	2021	2022	2021
Reported Income Before Tax by Segment	\$ 2,930	1,573	15,901	17,969	4,607	4,373	(624)	(1,072)	(1,089)	(67)	21,725	22,776
<b>% to Sales</b>	<b>19.6%</b>	<b>10.5%</b>	<b>30.3%</b>	<b>34.8%</b>	<b>16.8%</b>	<b>16.2%</b>	<b>-0.7%</b>	<b>-1.1%</b>	<b>-1.1%</b>	<b>-0.1%</b>	<b>22.9%</b>	<b>24.3%</b>
Intangible asset amortization expense	361	414	2,911	3,258	1,033	1,025	-	-	-	-	4,305	4,697
In-process research and development	-	-	783	-	-	900	-	-	-	-	783	900
Litigation related	150	1,603	104	640	612	85	-	-	-	-	866	2,328
Loss/(gain) on securities	-	(18)	696	(486)	(6)	(29)	-	-	-	-	690	(533)
Restructuring related	91	119	63	76	309	278	-	-	-	-	463	473
Acquisition, integration and divestiture related	-	-	(104)	(562)	300	84	-	-	-	-	196	(478)
Medical Device Regulation	-	-	-	-	296	234	-	-	-	-	296	234
COVID-19 Vaccine related costs	-	-	1,474	-	-	-	-	-	-	-	1,474	-
Consumer Health separation costs	-	-	-	-	-	-	-	-	1,089	67	1,089	67
Other	-	-	-	-	-	-	(7)	-	-	-	(7)	-
Adjusted Income Before Tax by Segment	\$ <u>3,532</u>	<u>3,691</u>	<u>21,828</u>	<u>20,895</u>	<u>7,151</u>	<u>6,950</u>	<u>(631)</u>	<u>(1,072)</u>	<u>-</u>	<u>-</u>	<u>31,880</u>	<u>30,464</u>
<b>% to Sales</b>	<b>23.6%</b>	<b>24.5%</b>	<b>41.5%</b>	<b>40.4%</b>	<b>26.1%</b>	<b>25.7%</b>	<b>-0.7%</b>	<b>-1.1%</b>	<b>0.0%</b>	<b>0.0%</b>	<b>33.6%</b>	<b>32.5%</b>

<sup>1</sup> Prior year income before tax has been reclassified as Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes

\*Estimated as of 1/24/2023

**Johnson & Johnson and Subsidiaries**  
**GAAP to Non-GAAP Reconciliation**  
**\$ in Millions**

**Quarter to Date**

	Fourth Quarter Jan 1, 2023 GAAP	Intangible asset amortization	Litigation related	In-process research and development	Restructuring related	Acquisition, integration and divestiture related (1)	(Loss)/gain on securities	Medical Device Regulation	COVID-19 Vaccine Related Costs	Consumer Health separation costs	Consumer Health separation tax related costs	Tax legislation and other tax related	Other	Fourth Quarter Jan 1, 2023 Non-GAAP
Cost of products sold	\$ 7,765	(1,060)			(36)			(33)	(160)	(4)	-	-	-	6,472
Selling, marketing and admin expenses	6,512							(9)	-	(43)				6,460
Research and development expense	3,841							(46)	(114)	-				3,681
Other (Income) / Expense	1,207	(1)	(262)		(20)	(196)	(6)		(547)	(423)	-		-	(248)
In-process research and development	173			(173)										-
Restructuring	84				(84)									-
Provision for taxes on income	681	165	(36)	40	21	5	2	17	199	94	(35)	47	-	1,200
Net Earnings	3,520	896	298	133	119	191	4	71	622	376	35	(47)	-	6,218

	Fourth Quarter Jan 2, 2022 GAAP	Intangible asset amortization	Litigation related	In-process research and development	Restructuring related	Acquisition, integration and divestiture related (1)	(Loss)/gain on securities	Medical Device Regulation	COVID-19 Vaccine Related Costs	Consumer Health separation costs	Consumer Health separation tax related costs	Tax legislation and other tax related	Other	Fourth Quarter Jan 2, 2022 Non-GAAP
Cost of products sold	\$ 7,955	(1,111)			(21)			(26)						6,797
Selling, marketing and admin expenses	7,154							(7)						7,147
Research and development expense	4,720							(40)						4,680
Other (Income) / Expense	9	(10)	(274)		(36)	(26)	198		-	(67)	-		-	(206)
In-process research and development	-			-										-
Restructuring	83				(83)									-
Provision for taxes on income	100	162	49	-	27	6	(89)	14	-	15	-	377	-	661
Net Earnings	4,736	959	225	-	113	20	(109)	59	-	52	-	(377)	-	5,678

**Year to Date**

	Twelve Months Jan 1, 2023 GAAP	Intangible asset amortization	Litigation related	In-process research and development	Restructuring related	Acquisition, integration and divestiture related (1)	(Loss)/gain on securities	Medical Device Regulation	COVID-19 Vaccine Related Costs	Consumer Health separation costs	Consumer Health separation tax related costs	Tax legislation and other tax related	Other	Twelve Months Jan 1, 2023 Non-GAAP
Cost of products sold	\$ 31,089	(4,292)			(82)			(109)	(456)	(4)				26,146
Selling, marketing and admin expenses	24,765							(28)		(45)				24,692
Research and development expense	14,603							(159)	(304)					14,140
Other (Income) / Expense	1,871	(13)	(866)		(60)	(196)	(690)		(714)	(1,040)	-		7	(1,701)
In-process research and development	783			(783)										-
Restructuring	321				(321)									-
Provision for taxes on income	3,784	667	(125)	178	81	5	166	56	360	206	(494)	(40)	(2)	4,842
Net Earnings	17,941	3,638	991	605	382	191	524	240	1,114	883	494	40	(5)	27,038

	Twelve Months Jan 2, 2022 GAAP	Intangible asset amortization	Litigation related	In-process research and development	Restructuring related	Acquisition, integration and divestiture related (1)	(Loss)/gain on securities	Medical Device Regulation	COVID-19 Vaccine Related Costs	Consumer Health separation costs	Consumer Health separation tax related costs	Tax legislation and other tax related	Other	Twelve Months Jan 2, 2022 Non-GAAP
Cost of products sold	\$ 29,855	(4,661)			(86)			(85)						25,023
Selling, marketing and admin expenses	24,659							(24)						24,635
Research and development expense	14,714							(125)						14,589
Other (Income) / Expense	489	(36)	(2,328)		(135)	478	533		-	(67)	-		-	(1,066)
In-process research and development	900			(900)										-
Restructuring	252				(252)									-
Provision for taxes on income	1,898	667	481	202	86	(98)	(116)	44	-	15	-	1,090	-	4,269
Net Earnings	20,878	4,030	1,847	698	387	(380)	(417)	190	-	52	-	(1,090)	-	26,195

(1) 2021 primarily includes gains on the divestitures of two Pharmaceutical brands outside of the United States.